Pain and treatment outcomes after initiating methadone vs buprenorphine among medicare patients with opioid use disorder and comorbid chronic pain: A target trial emulation
PLOS Medicine · 26.03.2026 · 23 (3) · e1004846
DOI: 10.1371/journal.pmed.1004846 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift PLOS Medicine, online erschienen am 26.03.2026. Verfasst von Yu-Jung Jenny Wei und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio, United States of America. Hauptthemen laut MEDLINE: Methadone, Buprenorphine, Chronic Pain, Opioid-Related Disorders. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agency for Healthcare Research and Quality.
Themen: Sucht und Abhängigkeit, Schmerzmanagement
Abstract (Originalsprache)
Background
Methadone and buprenorphine, effective treatments for opioid use disorder (OUD), also provide analgesia for managing pain, which is commonly experienced by patients with OUD. Limited population-based evidence exists comparing pain-related and treatment outcomes for methadone versus buprenorphine among patients with OUD and comorbid pain. The study aims to examine pain-related and treatment outcomes among Medicare patients with comorbid pain and OUD who initiated methadone or buprenorphine. Methods and findings We conducted a retrospective cohort study with target trial emulation using the 100% Medicare data from 2020 to 2023. Participants included patients with comorbid chronic pain and OUD who initiated methadone or buprenorphine. The key dependent variables were pain-related outcomes that included hospitalization and emergency department (ED) visit due to pain, and treatment outcomes that included opioid overdose and all-cause mortality. Outcomes were assessed 1 year following treatment initiation. Intention-to-treat and per-protocol analyses were conducted to estimate incidence rate ratios (IRRs) for pain-related outcomes and opioid overdose and hazard ratios (HRs) for all-cause mortality. For each outcome, we also calculated the adjusted risk difference (aRD) between the methadone and buprenorphine groups. We identified 49,727 eligible Medicare patients (mean [SD] age, 59.0 [11.6] years; 24,538 [49.3%] female and 25,189 [50.7%] male). Of the identified patients, 16,174 (32.5%) initiated methadone solely administered at opioid treatment programs, and 33,553 (67.5%) initiated buprenorphine primarily prescribed at office-based clinics. Compared with buprenorphine, initiation of methadone was associated with lower adjusted incidence rates of pain-related hospitalization (IRR, 0.64 (95% CI [0.58, 0.70]; P < .001); aRD, −7.2 (95% CI [−8.8 to −5.7]) per 1,000 person-years) and ED visit (IRR, 0.87 (95% CI [0.82, 0.92]; P < .001); aRD, −10.2 (95% CI [−14.4, −5.9]) per 1,000 person-years) in per-protocol analyses, with no difference in opioid overdose (IRR, 1.02 (95% CI [0.93,1.10]; P = .72); aRD, 0.33 (95% CI [−1.5, 2.1]) per 1,000 person-years) and all-cause mortality (HR, 1.06 (95% CI, [0.81–1.39]; P = .66); aRD, 1.1 (95% CI [−1.3, 1.0]) per 1,000 person-years) rates. Similar results were observed in intention-to-treat analyses. Main study limitations included unmeasured confounders and limited generalizability.
Conclusions
This population-based cohort study of Medicare patients with comorbid chronic pain and OUD found that methadone administered at opioid treatment programs is associated with reduced hospitalizations and ED visits for pain-related visits while offering treatment outcomes similar to buprenorphine primarily prescribed at office-based clinics. The favorable pain-related outcomes in patients with methadone should be interpreted with caution, as the finding may reflect differences in the underlying patient population, treatment dosing practices, pharmacological properties, and treatment practice settings, which cannot be measured in Medicare data and merit further investigations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio, United States of America.
- Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, Florida, United States of America.
- Center for Drug Evaluation and Safety, University of Florida, Gainesville, Florida, United States of America.
- Department of Epidemiology, Colleges of Medicine and Public Health & Health Professions, University of Florida, Gainesville, Florida, United States of America.
- Pain Research and Intervention Center of Excellence, University of Florida, Gainesville, Florida, United States of America.
- Department of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, Florida, United States of America.
ORCID-Profile: Yu-Jung Jenny Wei, Almut G Winterstein, Stephan Schmidt, Siegfried Schmidt
Förderung
- Agency for Healthcare Research and Quality
Zitieren
APA
Wei, Y. J., Winterstein, A. G., Fillingim, R. B., Schmidt, S., & Schmidt, S. (2026). Pain and treatment outcomes after initiating methadone vs buprenorphine among medicare patients with opioid use disorder and comorbid chronic pain: A target trial emulation. PLOS Medicine, 23(3), e1004846. https://doi.org/10.1371/journal.pmed.1004846
Vancouver
Wei YJ, Winterstein AG, Fillingim RB, Schmidt S, Schmidt S. Pain and treatment outcomes after initiating methadone vs buprenorphine among medicare patients with opioid use disorder and comorbid chronic pain: A target trial emulation. PLOS Medicine. 2026;23(3):e1004846. doi:10.1371/journal.pmed.1004846
BibTeX
@article{Wei2026,
author = {Wei, Yu-Jung Jenny and Winterstein, Almut G and Fillingim, Roger B and Schmidt, Stephan and Schmidt, Siegfried},
title = {Pain and treatment outcomes after initiating methadone vs buprenorphine among medicare patients with opioid use disorder and comorbid chronic pain: A target trial emulation},
journal = {PLOS Medicine},
year = {2026},
volume = {23},
number = {3},
pages = {e1004846},
doi = {10.1371/journal.pmed.1004846}
}
EUVIMED